Showing results (1-10 of 686) with videos related to

Sort By:
Pageof 69
Biochimica Et Biophysica Acta|April 13, 2007
Safety issues and prospects for future generations of PPAR modulatorsAnne Rubenstrunk, Rémy Hanf, Dean W Hum, et al.
Diabetes|July 28, 2005
Therapeutic roles of peroxisome proliferator-activated receptor agonistsBart Staels, Jean-Charles Fruchart
Hepatology (Baltimore, Md.)|May 25, 2013
Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitisBart Staels, Anne Rubenstrunk, Benoit Noel, et al.
Current Opinion in Pharmacology|September 16, 2006
PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndromeCatherine Fiévet, Jean-Charles Fruchart, Bart Staels
Nature Clinical Practice. Endocrinology & Metabolism|January 24, 2007
Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptorsPhilippe Gervois, Jean-Charles Fruchart, Bart Staels
Current Opinion in Lipidology|September 23, 2003
Peroxisome proliferator-activated receptors: new targets for the pharmacological modulation of macrophage gene expression and functionGiulia Chinetti, Jean-Charles Fruchart, Bart Staels
Frontiers in Bioscience : a Journal and Virtual Library|May 9, 2007
Genetically-engineered animals as research models for atherosclerosis: their use for the characterization of PPAR agonists in the treatment of cardiometabolic disordersCatherine Fievet, Jean-Charles Fruchart, Bart Staels
Molecular Endocrinology (Baltimore, Md.)|August 30, 2008
Phosphorylation of farnesoid X receptor by protein kinase C promotes its transcriptional activityRomain Gineste, Audrey Sirvent, Réjane Paumelle, et al.
FEBS Letters|May 19, 2004
The farnesoid X receptor induces very low density lipoprotein receptor gene expressionAudrey Sirvent, Thierry Claudel, Geneviève Martin, et al.
Diabetes & Vascular Disease Research|September 13, 2014
The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effectsRémy Hanf, Lesley J Millatt, Bertrand Cariou, et al.
Pageof 69